Biopharma Co. Sues Over Cancer Drug Clinical Trial Mix-Up

Law360, New York (September 26, 2012, 2:40 PM ET) -- Peregrine Pharmaceuticals Inc. on Monday sued a clinical testing company in California federal court, alleging it mixed up the results of a clinical trial for a new cancer treatment, causing Peregrine to have to rescind its promising trial results.

According to the Tustin, Calif.-based biopharmaceutical company’s complaint, Fargo, N.D.-based Clinical Supplies Management Inc. ran one of three randomized, double-blind, placebo-controlled Phase II trials for the drug bavituximab as part of a testing services agreement with Peregrine. Bavituximab, a first-of-its-kind monoclonal antibody treatment that prompts the immune system...
To view the full article, take a free trial now.
Try Law360 for free for seven days
Already a subscriber? Click here to login

Already have access?

  1. Forgot your password?
  2. Sign In

Get instant access to the one-stop news source for business lawyers

Required